SMO and acute myeloid leukemia: Only recently, the SMO antagonist glasdegib (PF-04449913, DAURISMOTM) has been approved in combination with low-dose chemotherapy for the treatment of acute myeloid leukemia patients after clinical studies have shown nearly a doubling of the overall survival of AML patients if glasdegib is included in the low-dose chemotherapy regimen [32, 33].